Theyre no where near the end of the ph3 its still not fully enrolled c'mon
yes, huge diff in trial number i agree.
However, from an end 2025 standpoint, per and or dxb either get approval from fda or they dont. Whoever does... if the other doesnt will be mile$ ahead, if they both dont, dxb w
ill be ahead, if they both do = same.
Im only factoring in a 2025 like for like dxb comparision, and by that metric they are v similar.
Theyre no where near the end of the ph3 its still not fully...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |